Ioannis Konstantinidis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ioannis Konstantinidis has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
Alison Morris
Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ
4 shared publications- Alison Morris
Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh, Pittsburgh, PA
3 shared publications - Ken M. Kunisaki
Minneapolis VA Health Care System, Minneapolis, MN, USA; University of Minnesota, Minneapolis, MN, USA
3 shared publications - Kristina Crothers
Division of Pulmonary, Critical Care, and Sleep Medicine, University of Washington, Seattle, Washington
3 shared publications - Michael Bradley Drummond
Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3 shared publications - Seyed Mehdi Nouraie
Department of Medicine, University of Pittsburgh, Pittsburgh, PA
3 shared publications
Latest Publications
- 3 November 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Advances in HIV-associated pulmonary diseases: an official American Thoracic Society workshop report
People with HIV (PWH) are at increased risk of a broad range of infectious and non-infectious pulmonary diseases. Since the last ATS Workshop on HIV-associated pulmonary disease, large national and international cohorts have demonstrated ongoing gaps in our understanding of lung disease in this vulnerable population that range from underappreciation of disease incidence and prevalence to lack of targeted treatments. Translational work on the underlying mechanisms of disease has demonstrated novel, HIV-specific mechanisms that may lend themselves to tailored therapies. Twenty-four experts in HIV-associated lung disease from across the translational spectrum were invited to participate in this ATS-sponsored Workshop utilizing a modified Delphi method that included a series of pre- and post-workshop electronic surveys and a two-day virtual workshop. Lung disease among PWH is driven by complex and interrelated mechanisms including persistent immune dysregulation, oxidative stress, accelerated aging, and microbiome alterations. Despite these advances in our understanding, important gaps persist between mechanistic insights and clinical care that include limited HIV-specific trials, underrepresentation of PWH in studies of lung disease, and the absence of tailored care strategies. These gaps are further accentuated by substantial variation in the availability of data from the most affected populations, particularly in sub-Saharan Africa and among children and adolescents. Overcoming these challenges will require coordinated, globally representative research efforts that leverage large cohorts, integrate multi-omics and longitudinal phenotyping, use mechanistic insights to inform clinical trials, and consider implementation science approaches with the ultimate goal of developing tailored prevention and treatment strategies for HIV-associated pulmonary diseases.
- 3 November 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Advances in HIV-associated pulmonary diseases: an official American Thoracic Society workshop report
People with HIV (PWH) are at increased risk of a broad range of infectious and non-infectious pulmonary diseases. Since the last ATS Workshop on HIV-associated pulmonary disease, large national and international cohorts have demonstrated ongoing gaps in our understanding of lung disease in this vulnerable population that range from underappreciation of disease incidence and prevalence to lack of targeted treatments. Translational work on the underlying mechanisms of disease has demonstrated novel, HIV-specific mechanisms that may lend themselves to tailored therapies. Twenty-four experts in HIV-associated lung disease from across the translational spectrum were invited to participate in this ATS-sponsored Workshop utilizing a modified Delphi method that included a series of pre- and post-workshop electronic surveys and a two-day virtual workshop. Lung disease among PWH is driven by complex and interrelated mechanisms including persistent immune dysregulation, oxidative stress, accelerated aging, and microbiome alterations. Despite these advances in our understanding, important gaps persist between mechanistic insights and clinical care that include limited HIV-specific trials, underrepresentation of PWH in studies of lung disease, and the absence of tailored care strategies. These gaps are further accentuated by substantial variation in the availability of data from the most affected populations, particularly in sub-Saharan Africa and among children and adolescents. Overcoming these challenges will require coordinated, globally representative research efforts that leverage large cohorts, integrate multi-omics and longitudinal phenotyping, use mechanistic insights to inform clinical trials, and consider implementation science approaches with the ultimate goal of developing tailored prevention and treatment strategies for HIV-associated pulmonary diseases.
- 28 March 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (7) , 1001-1008
Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Management of Community-acquired Pneumonia
CME will be available for this article at https://atsedplus.thoracic.org/content/beyond-protocol-integrating-trauma-informed-principles-clinical-research-icu-survivors
- 28 March 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 23 (7) , 1001-1008
Summary for Clinicians: Clinical Practice Guideline for the Diagnosis and Management of Community-acquired Pneumonia
CME will be available for this article at https://atsedplus.thoracic.org/content/beyond-protocol-integrating-trauma-informed-principles-clinical-research-icu-survivors
- 12 March 2025
- Published by Wolters Kluwer Health in AIDS
- Vol. 39 (9) , 1235-1245
Effect of HIV on respiratory symptoms, health status, and exertional capacity
Objective: People with HIV (PWH) have increased risk for worse pulmonary function and increased emphysema. HIV has been proposed as a risk factor for respiratory patient-reported outcomes (PROs). We assessed the association of HIV with respiratory symptoms, respiratory health status, and functional exercise capacity. Design: Systematic review and meta-analysis. Methods: We searched PubMed, EMBASE, CENTRAL, CDSR, WoS, Scopus, CINAHL, and GIM through November 2023 for studies of PWH and people without HIV (PWOH) reporting respiratory PROs. Primary outcomes were activity-limiting dyspnea (defined as Modified Medical Research Council Dyspnea Scale score ≥2), respiratory health status by St. George's Respiratory Questionnaire (SGRQ), and exertional capacity by 6-min walking distance (6MWD). We performed random-effects meta-analyses estimating odds ratios (ORs) and mean differences with 95% confidence intervals (CIs). Results: We included 89 publications corresponding to 56 studies. HIV was associated with activity-limiting dyspnea (OR 1.67; 95% CI 1.05–2.65), worse respiratory health status (SGRQ mean difference 2.9 units; 95% CI 0.6–5.2), worse exertional capacity (6MWD mean difference −58.9 m; 95% CI −115.3 to −2.4), and chronic cough, dyspnea, phlegm, and wheeze (OR 1.38–1.78). Respiratory symptom and adverse respiratory health status risk was greatest in European PWH. Certainty of evidence was very low, primarily due to studies’ observational design and inconsistency. Conclusion: PWH have increased risk for worse respiratory PROs. Systematic respiratory PRO assessment should be incorporated into routine clinical care to facilitate active case-finding of chronic lung disease in PWH. Future studies should longitudinally co-assess objective physiologic measures and respiratory PROs.
- 12 March 2025
- Published by Wolters Kluwer Health in AIDS
- Vol. 39 (9) , 1235-1245
Effect of HIV on respiratory symptoms, health status, and exertional capacity
Objective: People with HIV (PWH) have increased risk for worse pulmonary function and increased emphysema. HIV has been proposed as a risk factor for respiratory patient-reported outcomes (PROs). We assessed the association of HIV with respiratory symptoms, respiratory health status, and functional exercise capacity. Design: Systematic review and meta-analysis. Methods: We searched PubMed, EMBASE, CENTRAL, CDSR, WoS, Scopus, CINAHL, and GIM through November 2023 for studies of PWH and people without HIV (PWOH) reporting respiratory PROs. Primary outcomes were activity-limiting dyspnea (defined as Modified Medical Research Council Dyspnea Scale score ≥2), respiratory health status by St. George's Respiratory Questionnaire (SGRQ), and exertional capacity by 6-min walking distance (6MWD). We performed random-effects meta-analyses estimating odds ratios (ORs) and mean differences with 95% confidence intervals (CIs). Results: We included 89 publications corresponding to 56 studies. HIV was associated with activity-limiting dyspnea (OR 1.67; 95% CI 1.05–2.65), worse respiratory health status (SGRQ mean difference 2.9 units; 95% CI 0.6–5.2), worse exertional capacity (6MWD mean difference −58.9 m; 95% CI −115.3 to −2.4), and chronic cough, dyspnea, phlegm, and wheeze (OR 1.38–1.78). Respiratory symptom and adverse respiratory health status risk was greatest in European PWH. Certainty of evidence was very low, primarily due to studies’ observational design and inconsistency. Conclusion: PWH have increased risk for worse respiratory PROs. Systematic respiratory PRO assessment should be incorporated into routine clinical care to facilitate active case-finding of chronic lung disease in PWH. Future studies should longitudinally co-assess objective physiologic measures and respiratory PROs.
- Open Access
- 5 February 2025
- Published by Elsevier in Sleep Medicine
- Vol. 128, 130-138
Comparative efficacy of non-pharmacological interventions for adults with sleep apnea: A systematic review and network meta-analysis
- 5 February 2025
- Published by Elsevier in Sleep Medicine
- Vol. 128, 130-138
Open AccessComparative efficacy of non-pharmacological interventions for adults with sleep apnea: A systematic review and network meta-analysis
- 1 February 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (2) , 274-284
Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis
Rationale: Obstructive lung disease (OLD) pathogenesis includes inhalational (e.g., smoking) and noninhalational mechanisms (e.g., infections). Human immunodeficiency virus (HIV) has been suggested as a novel OLD risk factor. Substantial data have recently emerged about its effects on lung function and structure, especially in low- to middle-income countries and regarding longitudinal lung function. Objectives: To assess the association of HIV infection with OLD, impaired gas exchange, and emphysema. Methods: In this systematic review and meta-analysis, we searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Science, Scopus, Cumulative Index to Nursing and Allied Health Literature, and Global Index Medicus through April 2023 for controlled and observational studies of people living with and without HIV reporting pulmonary function and/or emphysema. Primary outcomes were OLD by spirometry, gas exchange impairment by diffusing capacity of the lung for carbon monoxide, and visual emphysema by computed tomography. We performed random-effects meta-analyses using odds ratios (ORs) with 95% confidence intervals (CIs). This study was registered in PROSPERO (CRD42021268498). Results: We included 95 publications pertaining to 43 unique studies. HIV was associated with OLD (OR, 1.29; 95% CI, 1.02–1.63), impaired gas exchange (OR, 2.63; 95% CI, 0.96–7.24), emphysema (OR, 1.46; 95% CI, 1.02–2.09), and faster lung function decline. OLD risk was greatest in Africans with HIV. There were no gas exchange or emphysema data from Africa. The certainty of evidence was low to very low, primarily because of studies’ observational design. Conclusions: People living with HIV have increased risk for OLD, gas exchange impairment, faster lung function decline, and emphysema. OLD risk in HIV varies regionally. We recommend that both spirometry and diffusing capacity of the lung for carbon monoxide be measured in people living with HIV and respiratory symptoms. Future studies should develop and validate HIV-specific screening and case-finding strategies for chronic lung disease.
- 1 February 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (2) , 274-284
Effect of Human Immunodeficiency Virus on Lung Function and Structure: A Systematic Review and Meta-Analysis
Rationale: Obstructive lung disease (OLD) pathogenesis includes inhalational (e.g., smoking) and noninhalational mechanisms (e.g., infections). Human immunodeficiency virus (HIV) has been suggested as a novel OLD risk factor. Substantial data have recently emerged about its effects on lung function and structure, especially in low- to middle-income countries and regarding longitudinal lung function. Objectives: To assess the association of HIV infection with OLD, impaired gas exchange, and emphysema. Methods: In this systematic review and meta-analysis, we searched PubMed, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Web of Science, Scopus, Cumulative Index to Nursing and Allied Health Literature, and Global Index Medicus through April 2023 for controlled and observational studies of people living with and without HIV reporting pulmonary function and/or emphysema. Primary outcomes were OLD by spirometry, gas exchange impairment by diffusing capacity of the lung for carbon monoxide, and visual emphysema by computed tomography. We performed random-effects meta-analyses using odds ratios (ORs) with 95% confidence intervals (CIs). This study was registered in PROSPERO (CRD42021268498). Results: We included 95 publications pertaining to 43 unique studies. HIV was associated with OLD (OR, 1.29; 95% CI, 1.02–1.63), impaired gas exchange (OR, 2.63; 95% CI, 0.96–7.24), emphysema (OR, 1.46; 95% CI, 1.02–2.09), and faster lung function decline. OLD risk was greatest in Africans with HIV. There were no gas exchange or emphysema data from Africa. The certainty of evidence was low to very low, primarily because of studies’ observational design. Conclusions: People living with HIV have increased risk for OLD, gas exchange impairment, faster lung function decline, and emphysema. OLD risk in HIV varies regionally. We recommend that both spirometry and diffusing capacity of the lung for carbon monoxide be measured in people living with HIV and respiratory symptoms. Future studies should develop and validate HIV-specific screening and case-finding strategies for chronic lung disease.
- Top Cited PapersOpen Access
- 1 January 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (1) , 15-33
Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Background: On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. Methods: A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, de novo development of recommendations) methodology. Results: New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin. Conclusions: All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.
- 1 January 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (1) , 15-33
Top Cited PapersOpen AccessUpdates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Background: On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis. Methods: A Joint Panel representing multiple interdisciplinary perspectives convened with American Thoracic Society methodologists to review evidence and make recommendations using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) and GRADE-ADOLOPMENT (adoption, adaptation, and, as needed, de novo development of recommendations) methodology. Results: New drug-susceptible TB recommendations include the use of a novel 4-month regimen for people with pulmonary TB and a shortened 4-month regimen for children with nonsevere TB. Drug-resistant TB recommendation updates include the use of novel regimens containing bedaquiline, pretomanid, and linezolid with or without moxifloxacin. Conclusions: All-oral, shorter treatment regimens for TB are now recommended for use in eligible individuals.
- Open Access
- 24 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0309449
Impact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients
COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p = <0.0001), no differences in 30-day survival were observed between CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was numerically lower in recipients who were seronegative prior to CCP administration, compared to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units of high-titer CCP had numerically better survival versus those who received fewer high-titer units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day survival compared to propensity matched controls. Together these data support that CCP therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection.
- 24 October 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (10) , e0309449
Open AccessImpact of variable titer COVID-19 convalescent plasma and recipient SARS-CoV2-specific humoral immunity on survival in hospitalized patients
COVID-19 convalescent plasma (CCP) was one of the first therapies to receive emergency use authorization for management of COVID-19. We assessed the effectiveness of CCP in a propensity-matched analysis, and whether the presence of antibodies in the recipient at the time of treatment or the titer of antibodies in the administered CCP influenced clinical effectiveness. In an inpatient population within a single large health system, a total of 290 CCP patients were matched to 290 controls. While CCP increased titers of anti-SARS-CoV-2 RBD IgG titers post-CCP (p = <0.0001), no differences in 30-day survival were observed between CCP patients and controls in univariate and multivariate analyses. Survival at 30 days was numerically lower in recipients who were seronegative prior to CCP administration, compared to those with low titer and high titer anti-SARS-CoV-2 RBD IgG, respectively, but did not reach statistical significance (56% vs 82% vs 75%, p = 0.16). Patients who received 2 units of high-titer CCP had numerically better survival versus those who received fewer high-titer units, but this was not statistically significant (p = 0.08). CCP did not improve 30-day survival compared to propensity matched controls. Together these data support that CCP therapy provides limited benefit to hospitalized patients with SARS-CoV-2 infection.
- 1 December 2022
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19 (12) , 2013-2020
Pulmonary Function Trajectories in People with HIV: Analysis of the Pittsburgh HIV Lung Cohort
Rationale: Human immunodeficiency virus (HIV) infection is associated with chronic lung disease and impaired pulmonary function; however, longitudinal pulmonary function phenotypes in HIV are undefined. Objectives: To identify pulmonary function trajectories, their determinants, and outcomes. Methods: We used data from participants with HIV in the Pittsburgh HIV Lung Cohort with three or more pulmonary function tests between 2007 and 2020. We analyzed post-bronchodilator forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and diffusing capacity of the lung for carbon monoxide (Dl CO) using group-based trajectory modeling to identify subgroups of individuals whose measurements followed a similar pattern over time. We examined the association between participant characteristics and trajectories using multivariable logistic regression. In exploratory adjusted analyses restricted to individuals with available plasma cytokine data, we investigated the association between 18 individual standardized cytokine concentrations and trajectories. We compared mortality, dyspnea prevalence, respiratory health status, and 6-minute-walk distance between phenotypes. Results: A total of 265 participants contributed 1,606 pulmonary function measurements over a median follow-up of 8.1 years. We identified two trajectories each for FEV1 and FVC: “low baseline, slow decline” and “high baseline, rapid decline.” There were three trajectory groups for FEV1/FVC: “rapid decline,” “moderate decline,” and “slow decline.” Finally, we identified two trajectories for Dl CO: “baseline low” and “baseline high.” The low baseline, slow decline FEV1 and FVC, rapid decline, and moderate decline FEV1/FVC, and baseline low Dl CO phenotypes were associated with increased dyspnea prevalence, worse respiratory health status, and decreased 6-minute-walk distance. The baseline low Dl CO phenotype was also associated with worse mortality. Current smoking and pack-years of smoking were associated with the adverse FEV1, FEV1/FVC, and Dl CO phenotypes. Detectable viremia was the only HIV marker associated with the adverse Dl CO phenotype. C-reactive protein and endothelin-1 were associated with the adverse FEV1 and FVC phenotypes, and endothelin-1 trended toward an association with the adverse Dl CO phenotype. Conclusions: We identified novel, distinct longitudinal pulmonary function phenotypes with significant differences in characteristics and outcomes. These findings highlight the importance of lung dysfunction over time in people with HIV and should be validated in additional cohorts.
- 1 December 2022
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 19 (12) , 2013-2020
Pulmonary Function Trajectories in People with HIV: Analysis of the Pittsburgh HIV Lung Cohort
Rationale: Human immunodeficiency virus (HIV) infection is associated with chronic lung disease and impaired pulmonary function; however, longitudinal pulmonary function phenotypes in HIV are undefined. Objectives: To identify pulmonary function trajectories, their determinants, and outcomes. Methods: We used data from participants with HIV in the Pittsburgh HIV Lung Cohort with three or more pulmonary function tests between 2007 and 2020. We analyzed post-bronchodilator forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and diffusing capacity of the lung for carbon monoxide (Dl CO) using group-based trajectory modeling to identify subgroups of individuals whose measurements followed a similar pattern over time. We examined the association between participant characteristics and trajectories using multivariable logistic regression. In exploratory adjusted analyses restricted to individuals with available plasma cytokine data, we investigated the association between 18 individual standardized cytokine concentrations and trajectories. We compared mortality, dyspnea prevalence, respiratory health status, and 6-minute-walk distance between phenotypes. Results: A total of 265 participants contributed 1,606 pulmonary function measurements over a median follow-up of 8.1 years. We identified two trajectories each for FEV1 and FVC: “low baseline, slow decline” and “high baseline, rapid decline.” There were three trajectory groups for FEV1/FVC: “rapid decline,” “moderate decline,” and “slow decline.” Finally, we identified two trajectories for Dl CO: “baseline low” and “baseline high.” The low baseline, slow decline FEV1 and FVC, rapid decline, and moderate decline FEV1/FVC, and baseline low Dl CO phenotypes were associated with increased dyspnea prevalence, worse respiratory health status, and decreased 6-minute-walk distance. The baseline low Dl CO phenotype was also associated with worse mortality. Current smoking and pack-years of smoking were associated with the adverse FEV1, FEV1/FVC, and Dl CO phenotypes. Detectable viremia was the only HIV marker associated with the adverse Dl CO phenotype. C-reactive protein and endothelin-1 were associated with the adverse FEV1 and FVC phenotypes, and endothelin-1 trended toward an association with the adverse Dl CO phenotype. Conclusions: We identified novel, distinct longitudinal pulmonary function phenotypes with significant differences in characteristics and outcomes. These findings highlight the importance of lung dysfunction over time in people with HIV and should be validated in additional cohorts.
- Open Access
- 1 October 2021
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 18 (10) , 1753
The Impact of Acute Illness Severity on Post–COVID-19 Sequelae Remains an Unsettled Question
- 1 October 2021
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 18 (10) , 1753
Open AccessThe Impact of Acute Illness Severity on Post–COVID-19 Sequelae Remains an Unsettled Question